f | { | f | { |
n | | n | "author": "", |
| | | "author_email": "", |
| "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", | | "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", |
| "groups": [ | | "groups": [ |
| { | | { |
| "description": "Group for guidelines", | | "description": "Group for guidelines", |
| "display_name": "Guideline", | | "display_name": "Guideline", |
| "id": "88e0ef3f-7d7e-44a5-9234-084f8c170d82", | | "id": "88e0ef3f-7d7e-44a5-9234-084f8c170d82", |
| "image_display_url": | | "image_display_url": |
| 3-17-123643.7336343533402businessmanagementplanprojectreporticon.png", | | 3-17-123643.7336343533402businessmanagementplanprojectreporticon.png", |
| "name": "guideline", | | "name": "guideline", |
| "title": "Guideline" | | "title": "Guideline" |
| } | | } |
| ], | | ], |
| "id": "94594fe2-1e26-4345-a1b2-76946f296df7", | | "id": "94594fe2-1e26-4345-a1b2-76946f296df7", |
| "isopen": false, | | "isopen": false, |
n | "license_title": null, | n | "license_id": "notspecified", |
| | | "license_title": "License not specified", |
| "maintainer": null, | | "maintainer": null, |
| "maintainer_email": null, | | "maintainer_email": null, |
| "metadata_created": "2021-09-16T08:11:57.651981", | | "metadata_created": "2021-09-16T08:11:57.651981", |
n | "metadata_modified": "2022-04-04T09:44:09.419751", | n | "metadata_modified": "2022-04-25T17:55:35.142864", |
| "name": "malawi-cotrimoxazole-preventive-therapy-guidelines-2005", | | "name": "malawi-cotrimoxazole-preventive-therapy-guidelines-2005", |
n | | n | "notes": "New and recent evidence (see references 1-12) shows that |
| | | cotrimoxazole (CTX) preventive therapy is associated with a 25-46% |
| | | reduction in mortality in sub-Saharan Africa, even in areas with high |
| | | bacterial resistance to the antibiotic. CTX preventive therapy also |
| | | decreases the frequency of clinic visits and hospitalisations, |
| | | improves weight and reverses the decline in CD4-lymphocyte counts and |
| | | the rise in HIV viral loads. Efficacy seems to be maintained over the |
| | | 1-2 year follow-up periods of the studies. CTX preventive therapy in |
| | | Africa has few adverse reactions and there are high levels of |
| | | adherence. In summary, CTX is a safe, cheap and readily available |
| | | anti-microbial agent, which can extend and improve the quality of |
| | | life.", |
| "num_resources": 1, | | "num_resources": 1, |
| "num_tags": 0, | | "num_tags": 0, |
| "organization": { | | "organization": { |
| "approval_status": "approved", | | "approval_status": "approved", |
| "created": "2021-10-14T11:02:35.234558", | | "created": "2021-10-14T11:02:35.234558", |
n | "description": "Department of HIV & AIDS and Viral Hepatitis", | n | "description": "The Department of HIV & AIDS (DHA) was established |
| | | in 2001, initially as a unit in the Department of Clinical Services, |
| | | to coordinate the biomedical HIV Program in Malawi. The department now |
| | | carries responsibility for various HIV related programs including: |
| | | sexually transmitted infections (STIs), prevention of mother to child |
| | | transmission of HIV (PMTCT), and national voluntary male medical |
| | | circumcision program (VMMC). All these HIV program sub-sections are |
| | | linked to one robust monitoring and evaluation sub-section in the HIV |
| | | and AIDS Department which technically operates under the Central |
| | | Monitoring and Evaluation Department (CMED) of the Ministry of |
| | | Health.", |
| "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
n | "image_url": "", | n | "image_url": |
| | | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", |
| "is_organization": true, | | "is_organization": true, |
| "name": "dha", | | "name": "dha", |
| "state": "active", | | "state": "active", |
t | "title": "Department of HIV & AIDS", | t | "title": "Department of HIV & AIDS and Viral Hepatitis", |
| "type": "organization" | | "type": "organization" |
| }, | | }, |
| "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "private": false, | | "private": false, |
| "program_area": "Care and Treatment", | | "program_area": "Care and Treatment", |
| "relationships_as_object": [], | | "relationships_as_object": [], |
| "relationships_as_subject": [], | | "relationships_as_subject": [], |
| "resources": [ | | "resources": [ |
| { | | { |
| "cache_last_updated": null, | | "cache_last_updated": null, |
| "cache_url": null, | | "cache_url": null, |
| "created": "2022-03-23T19:56:02.552882", | | "created": "2022-03-23T19:56:02.552882", |
| "description": "", | | "description": "", |
| "format": "PDF", | | "format": "PDF", |
| "hash": "", | | "hash": "", |
| "id": "91ae55ee-aca3-4fd4-9862-19e4a5830098", | | "id": "91ae55ee-aca3-4fd4-9862-19e4a5830098", |
| "last_modified": "2022-04-04T09:44:09.393005", | | "last_modified": "2022-04-04T09:44:09.393005", |
| "lfs_prefix": | | "lfs_prefix": |
| "dha/malawi-cotrimoxazole-preventive-therapy-guidelines-2005", | | "dha/malawi-cotrimoxazole-preventive-therapy-guidelines-2005", |
| "metadata_modified": "2022-04-04T09:44:09.426317", | | "metadata_modified": "2022-04-04T09:44:09.426317", |
| "mimetype": "application/pdf", | | "mimetype": "application/pdf", |
| "mimetype_inner": null, | | "mimetype_inner": null, |
| "name": | | "name": |
| "malawi-cotrimoxazole-preventive-therapy-guidelines-2005", | | "malawi-cotrimoxazole-preventive-therapy-guidelines-2005", |
| "package_id": "94594fe2-1e26-4345-a1b2-76946f296df7", | | "package_id": "94594fe2-1e26-4345-a1b2-76946f296df7", |
| "position": 0, | | "position": 0, |
| "resource_type": null, | | "resource_type": null, |
| "sha256": | | "sha256": |
| "3248a366e50bcb4ed1acc30ee7c22f4d4107112b730381236ff548b5db5a33c1", | | "3248a366e50bcb4ed1acc30ee7c22f4d4107112b730381236ff548b5db5a33c1", |
| "size": 38334, | | "size": 38334, |
| "state": "active", | | "state": "active", |
| "url": | | "url": |
| download/malawi-cotrimoxazole-prevention-therapy-guidelines-2005.pdf", | | download/malawi-cotrimoxazole-prevention-therapy-guidelines-2005.pdf", |
| "url_type": "upload" | | "url_type": "upload" |
| } | | } |
| ], | | ], |
| "state": "active", | | "state": "active", |
| "tags": [], | | "tags": [], |
| "title": "Malawi Cotrimoxazole Preventive Therapy Guidelines 2005", | | "title": "Malawi Cotrimoxazole Preventive Therapy Guidelines 2005", |
| "type": "dataset", | | "type": "dataset", |
| "url": null, | | "url": null, |
| "version": null, | | "version": null, |
| "year": "2005" | | "year": "2005" |
| } | | } |